metformin has been researched along with Nephrosclerosis in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Nephrosclerosis: Hardening of the KIDNEY due to infiltration by fibrous connective tissue (FIBROSIS), usually caused by renovascular diseases or chronic HYPERTENSION. Nephrosclerosis leads to renal ISCHEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JH | 1 |
| Kim, JH | 1 |
| Kim, JS | 1 |
| Chang, JW | 1 |
| Kim, SB | 1 |
| Park, JS | 1 |
| Lee, SK | 1 |
1 other study available for metformin and Nephrosclerosis
| Article | Year |
|---|---|
AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition.
Topics: Albumins; Aldosterone; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Angiotensin II; Ce | 2013 |